Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptose Biosciences Inc.APTO · Entity 33387 | Director | February 05, 2024 | February 07, 2024 |
| Elicio Therapeutics, Inc.ELTX · Entity 299 | Director | August 31, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptose Biosciences Inc.
Report date February 05, 2024 · Filed February 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2034-02-05 | Direct | 3,333 |
Reported balance
After 2024-02-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-05 · Grant · Acquired 3,333 · Balance 3,333 F1: The options vest as follows: 50% on February 5, 2025; 25% on February 5, 2026; and 25% on February 5, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest as follows: 50% on February 5, 2025; 25% on February 5, 2026; and 25% on February 5, 2027.
Elicio Therapeutics, Inc.
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2036-08-31 | Direct | 21,750 |
Reported balance
After 2026-08-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-31 · Grant · Acquired 21,750 · Balance 21,750 F1: The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 20:04 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 21,750 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001761748-26-000002 · wk-form4_1788379493.xml · derivative · entry 1 Ashe Carol Gail · CIK 0001761748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,750 Underlying: Common Stock · 21,750 shares Expires 2036-08-31 F1 · derivative.exercise_date: The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders. Read SEC document |
| May 19, 2025 Filed May 20, 2025 16:08 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 7,900 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001601485-25-000090 · wk-form4_1747771672.xml · derivative · entry 1 Ashe Carol Gail · CIK 0001761748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,900 Underlying: Common Stock · 7,900 shares Expires 2035-05-19 F1 · shares: The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. F1 · derivative.exercise_date: The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 07:36 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 4,100 | $0.00 Strike: $5.12 | $0.00 |
DisclosureSEC source: 0001601485-24-000097 · wk-form4_1732538168.xml · derivative · entry 1 Ashe Carol Gail · CIK 0001761748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,100 Underlying: Common Stock · 4,100 shares Expires 2034-11-21 F1 · shares: The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. F1 · derivative.exercise_date: The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 21:44 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantDirector Stock Option (Right to Buy) · Derivative | 3,333 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0000912282-24-000120 · form4.xml · derivative · entry 1 Ashe Carol Gail · CIK 0001761748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Shares · 3,333 shares Expires 2034-02-05 F1 · derivative.exercise_date: The options vest as follows: 50% on February 5, 2025; 25% on February 5, 2026; and 25% on February 5, 2027. Read SEC document |
| December 28, 2023 Filed Dec 29, 2023 17:05 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (right to buy) · Derivative | 4,100 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001140361-23-060236 · form4.xml · derivative · entry 1 Ashe Carol Gail · CIK 0001761748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,100 Underlying: Common Stock · 4,100 shares Expires 2033-12-28 F1 · shares: The stock option, granted in lieu of the annual equity award under the Issuer's Amended and Restated Non-Employee Director Compensation Policy, vests in full on the earlier of (A) December 28, 2024, the one-year anniversary of the grant date, or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. F1 · derivative.exercise_date: The stock option, granted in lieu of the annual equity award under the Issuer's Amended and Restated Non-Employee Director Compensation Policy, vests in full on the earlier of (A) December 28, 2024, the one-year anniversary of the grant date, or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
| January 19, 2023 Filed Jan 24, 2023 00:51 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantDirector Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001567619-23-001155 · doc1.xml · derivative · entry 1 Ashe Carol Gail · CIK 0001761748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2033-11-19 F1 · derivative.exercise_date: Fifty percent (50%) of the options vest on January 19, 2024, twenty-five percent (25%) vest on January 19, 2025, and twenty-five percent (25%) vest on January 19, 2026. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 23:04 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantDirector Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001567619-22-001381 · doc1.xml · derivative · entry 1 Ashe Carol Gail · CIK 0001761748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2032-01-17 F1 · derivative.exercise_date: The options were granted on January 18, 2022, and vest as follows: 50% vest on January 18, 2023; 25% vest on January 18, 2024; and 25% vest on January 18, 2025. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:41 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantDirector Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001567619-21-000571 · doc1.xml · derivative · entry 1 Ashe Carol Gail · CIK 0001761748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2031-01-04 F1 · derivative.exercise_date: The options were granted on January 4, 2021, and vest as follows: 50% vest on January 4, 2022; 25% vest on January 4, 2023; and 25% vest on January 4, 2024. Read SEC document |
| March 11, 2020 Filed Mar 14, 2020 00:55 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantDirector Option Grant · Derivative | 50,000 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001567619-20-006350 · doc1.xml · derivative · entry 1 Ashe Carol Gail · CIK 0001761748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2030-03-10 Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 02:32 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantDirector Option Grant · Derivative | 65,000 | $0.00 Strike: $6.91 | $0.00 |
DisclosureSEC source: 0001567619-20-001972 · doc1.xml · derivative · entry 1 Ashe Carol Gail · CIK 0001761748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Shares · 65,000 shares Expires 2030-01-30 F1 · derivative.exercise_date: Fifty percent (50%) of the options vest on 1/31/2021. The remaining 50% vest as follows: one-half on 1/31/2022 and one-half on 1/31/2023. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 01:03 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantStock Options (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001567619-19-000419 · doc1.xml · derivative · entry 1 Ashe Carol Gail · CIK 0001761748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: The options vest fully on the first anniversary of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.